APA (7th ed.) Citation

Mitha, E., Ferguson, M., Wilhase, A. C., Looze, F. D., Vachon, M., Stacey, H., . . . Schwarz, T. F. (2026). Immunogenicity and Safety of the AS01E-adjuvanted Respiratory Syncytial Virus (RSV) Prefusion F Protein Vaccine in Adults Aged 18–49 Years at Increased Risk of RSV Disease Compared with Adults Aged ≥60 Years. Clinical Infectious Diseases, 82(5), e1093. https://doi.org/10.1093/cid/ciag058

Chicago Style (17th ed.) Citation

Mitha, Essack, et al. "Immunogenicity and Safety of the AS01E-adjuvanted Respiratory Syncytial Virus (RSV) Prefusion F Protein Vaccine in Adults Aged 18–49 Years at Increased Risk of RSV Disease Compared with Adults Aged ≥60 Years." Clinical Infectious Diseases 82, no. 5 (2026): e1093. https://doi.org/10.1093/cid/ciag058.

MLA (9th ed.) Citation

Mitha, Essack, et al. "Immunogenicity and Safety of the AS01E-adjuvanted Respiratory Syncytial Virus (RSV) Prefusion F Protein Vaccine in Adults Aged 18–49 Years at Increased Risk of RSV Disease Compared with Adults Aged ≥60 Years." Clinical Infectious Diseases, vol. 82, no. 5, 2026, p. e1093, https://doi.org/10.1093/cid/ciag058.